Reviews
Juvenile dermatomyositis. Where are we now?
L.J. Mccann1, P. Livermore2, M.G. Wilkinson3, L.R. Wedderburn4
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK. liza.mccann@alderhey.nhs.uk
- Paediatric Rheumatology Matron and BRC Clinical Academic Programme Lead, Great Ormond Street Children’s Hospital NHS Foundation Trust, London; NIHR Biomedical Research Centre at Great Ormond Street Hospital, London, and Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH and GOSH, London, UK.
- Centre for Adolescent Rheumatology Versus Arthritis at UCL UCLH and GOSH, NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children (GOSH) and UCL GOS Institute of Child Health, London, UK.
- Centre for Adolescent Rheumatology Versus Arthritis at UCL UCLH and GOSH, NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children (GOSH) and UCL GOS Institute of Child Health, London, UK.
CER15205
2022 Vol.40, N°2
PI 0394, PF 0403
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 35225221 [PubMed]
Received: 01/10/2021
Accepted : 27/01/2022
In Press: 07/02/2022
Published: 25/02/2022
Abstract
Juvenile onset idiopathic inflammatory myopathy (IIM) has many similarities and distinct differences from adult-onset disease. This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common disease sub-type of IIM in childhood. JDM is a systemic immune mediated vasculopathy, increasingly recognised as a group of distinct phenotypes with variable presentation and outlook. This overview will describe long-term outlook and disease course including health-related quality of life and emerging treatments.
